• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression therapy treatment for depression

For a lot of people suffering from depression, traditional therapies and medication are ineffective. The individual approach to treatment could be the answer.

Cue is a digital intervention platform that transforms passively acquired sensor data from smartphones into customized micro-interventions that improve mental health. We examined the most effective-fitting personalized ML models to each person, using Shapley values to determine their characteristic predictors. The results revealed distinct characteristics that changed mood in a predictable manner over time.

Predictors of Mood

Depression During Pregnancy Treatment is a leading cause of mental illness across the world.1 Yet the majority of people with the condition receive treatment. To improve outcomes, clinicians need to be able to recognize and treat patients who have the highest likelihood of responding to specific treatments.

Personalized depression treatment is one method of doing this. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit the most from certain treatments. They are using mobile phone sensors as well as a voice assistant that incorporates artificial intelligence and other digital tools. With two grants awarded totaling more than $10 million, they will make use of these technologies to identify the biological and behavioral factors that determine the response to antidepressant medication and psychotherapy.

The majority of research on factors that predict depression treatment effectiveness has focused on the sociodemographic and clinical aspects. These include demographic factors like age, sex and educational level, clinical characteristics like symptom severity and comorbidities, and biological markers like neuroimaging and genetic variation.

Few studies have used longitudinal data to determine mood among individuals. Many studies do not take into consideration the fact that moods vary significantly between individuals. Therefore, it is important to develop methods which allow for the analysis and measurement of personal differences between mood predictors alternative treatments for depression, mood predictors, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to create algorithms that can systematically identify various patterns of behavior and emotion that vary between individuals.

In addition to these modalities, the team created a machine learning algorithm to model the dynamic factors that determine a person's depressed mood. The algorithm blends these individual characteristics into a distinctive "digital phenotype" for each participant.

This digital phenotype has been correlated with CAT DI scores which is a psychometrically validated symptom severity scale. However the correlation was tinny (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 x 10-03) and varied widely among individuals.

Predictors of Symptoms

Depression is the leading reason for disability across the world1, however, it is often not properly diagnosed and treated. Depression disorders are rarely treated due to the stigma associated with them and the lack of effective treatments.

To allow for individualized treatment, identifying factors that predict the severity of symptoms is crucial. The current methods for predicting symptoms rely heavily on clinical interviews, which are unreliable and only reveal a few features associated with depression.

Machine learning can enhance the accuracy of diagnosis and treatment for depression by combining continuous digital behavior phenotypes gathered from smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes allow continuous, high-resolution measurements. They also capture a variety of distinct behaviors and patterns that are difficult to capture through interviews.

The study enrolled University of California Los Angeles (UCLA) students with moderate to severe depressive symptoms. who were enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29 that was created under the UCLA Depression Grand Challenge. Participants were referred to online support or to clinical treatment according to the degree of their depression. Patients who scored high on the CAT-DI scale of 35 65 students were assigned online support by an instructor and those with a score 75 patients were referred to in-person psychotherapy.

At the beginning, participants answered an array of questions regarding their personal demographics and psychosocial characteristics. The questions covered age, sex, and education, marital status, financial status, whether they were divorced or not, current suicidal ideas, intent or attempts, as well as the frequency with which they consumed alcohol. The CAT-DI was used to rate the severity of depression symptoms on a scale of 0-100. CAT-DI assessments were conducted each other week for the participants who received online support and every week for those who received in-person care.

Predictors of Treatment Response

Research is focusing on personalization of treatment for depression. Many studies are aimed at identifying predictors, which will aid clinicians in identifying the most effective medications to treat each patient. Particularly, pharmacogenetics is able to identify genetic variants that determine the way that the body processes antidepressants. This allows doctors select medications that are likely to be the most effective for each patient, reducing the amount of time and effort required for trial-and-error treatments and eliminating any adverse effects.

Another promising method is to construct models for prediction using multiple data sources, including data from clinical studies and neural imaging data. These models can be used to identify which variables are most predictive of a particular outcome, such as whether a medication can help with symptoms or mood. These models can be used to determine a patient's response to treatment that is already in place which allows doctors to maximize the effectiveness of the treatment currently being administered.

A new type of research uses machine learning methods such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables and improve the accuracy of predictive. These models have been demonstrated to be useful in predicting treatment outcomes like the response to antidepressants. These methods are becoming popular in psychiatry, and it is likely that they will become the standard for future clinical practice.

Research into the underlying causes of depression continues, as do predictive models based on ML. Recent findings suggest that depression is linked to the dysfunctions of specific neural networks. This theory suggests that a individualized treatment for depression will be based on targeted therapies that restore normal functioning to these circuits.

Internet-based interventions are an option to accomplish this. They can offer a more tailored and individualized experience for patients. For instance, one study found that a program on the internet was more effective than standard care in alleviating symptoms and ensuring an improved quality of life for people suffering from MDD. In addition, a controlled randomized trial of a personalized approach to depression treatment showed steady improvement and decreased adverse effects in a significant proportion of participants.

Predictors of side effects

In the treatment of depression the biggest challenge is predicting and determining which antidepressant medications will have minimal or zero side negative effects. Many patients have a trial-and error approach, using a variety of medications being prescribed before settling on one that is safe and effective. Pharmacogenetics provides an exciting new method for an efficient and specific approach to choosing antidepressant medications.

Many predictors can be used to determine the best antidepressant ways to treat depression prescribe, such as gene variants, phenotypes of patients (e.g., sex or ethnicity) and co-morbidities. To determine the most reliable and reliable predictors for a specific treatment, randomized controlled trials with larger samples will be required. This is because the identifying of moderators or interaction effects may be much more difficult in trials that only take into account a single episode of treatment per person instead of multiple episodes of treatment over time.

Additionally, the prediction of a patient's response to a particular medication will likely also need to incorporate information regarding the symptom profile and comorbidities, and the patient's prior subjective experience of its tolerability and effectiveness. At present, only a handful of easily identifiable sociodemographic variables and clinical variables are reliable in predicting the response to MDD. These include age, gender and race/ethnicity, SES, BMI and the presence of alexithymia.

Many issues remain to be resolved when it comes to the use of pharmacogenetics in the treatment of depression. First, it is essential to have a clear understanding and definition of the genetic factors that cause depression, as well as an understanding of an accurate indicator of the response to treatment. Ethics like privacy, and the responsible use of genetic information should also be considered. Pharmacogenetics can eventually, reduce stigma surrounding mental health treatments and improve the quality of treatment. As with all psychiatric approaches, it is important to give careful consideration and implement the plan. The best option is to offer patients an array of effective depression medication options and encourage them to speak openly with their doctors about their experiences and concerns.